📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
8 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
NEUTRAL
TOTAL VIEWS
53
BSX Latest News & AI Sentiment Analysis
8 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 15 ARTICLES
Here’s What Hurt Boston Scientific Corporation (BSX) in Q2
Boston Scientific (BSX) appears as a holding discussion within a fund manager's quarterly investor letter, a routine procedural...
Here’s What Hurt Boston Scientific Corporation (BSX) in Q2
Boston Scientific (BSX) appears in TCW Funds' Q2 2026 investor letter as part of the 'TCW Concentrated Large Cap Growth Fund' portfolio...
Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone (NYSE:BSX)
Boston Scientific reported Q2 2026 revenues of $5.4 billion, demonstrating operational resilience despite acknowledged headwinds in key...
Boston Scientific Stock: Attempting The 2027 Reset (NYSE:BSX)
Boston Scientific (BSX) has reset forward guidance and publicly acknowledged heightened competitive pressures in its core medical device...
Boston Scientific beats second quarter expectations, raises full-year outlook
Boston Scientific delivered a beat-and-raise quarter, posting adjusted EPS of $0.86 versus $0.83 consensus while simultaneously...
Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript
Boston Scientific (BSX) released Q2 2026 earnings results via earnings call on July 29, 2026. The earnings call transcript alone,...
Boston Scientific Trims FY26 Outlook - Update
Boston Scientific Corp. (BSX) has reduced its full-year 2026 earnings and revenue guidance following second-quarter results, signaling...
Boston Scientific expects headcount reductions amid restructuring initiative
Boston Scientific has initiated a restructuring program with material near-term cost implications. The $700–800 million charge signals...
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
ViCentra, a European medical device innovator focused on insulin delivery systems, has appointed Ian Wells as Chief Financial Officer...
Boston Scientific: The Time Has Come To Catch This Falling Knife (NYSE:BSX)
Boston Scientific (BSX) is trading approximately 60% below recent highs, presenting a valuation reset in the medical device sector. This...
TD Cowen Maintains a Buy Rating on Boston Scientific (BSX)
Boston Scientific (BSX) has experienced significant sell-off pressure year-to-date, declining over 52%, yet maintains analyst conviction...
Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX)
Boston Scientific (BSX) has been identified as an oversold medical device stock with substantial recovery potential despite a June 12...
Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device
Boston Scientific (BSX) faces a notable headwind as Truist Securities reduced its price target by 24.7%, from $85 to $64, while...
Below Expected Outlook Pressured Boston Scientific (BSX) in Q1
Boston Scientific (BSX) faced downward pressure in Q1 2026 following a below-expected forward guidance, reflecting broader large-cap...
BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
Boston Scientific (BSX) has experienced substantial de-rating in 2026, trading down nearly 50% year-to-date as of June. Despite this...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice